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Abstract
Background: The aim of this study was to investigate the use of prophylactic magnesium sulphate
and amiodarone in treating arrhythmias that may occur following coronary bypass grafting
operations.
Methods: The study population consisted of 192 consecutive patients who were undergoing
coronary artery bypass grafting (CABG). Sixty-four patients were given 3 g of magnesium sulphate
(MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously
at the following times: 12 hours prior to the operation, immediately following the operation, and
on postoperative days 1, 2, and 3 (Group 1). Another group of 64 patients was given a preoperative
infusion of amiodarone (1200 mg) on first post-operative day (Group 2). After the operation
amiodarone was administered orally at a dose of 600 mg/day. Sixty-four patients in group 3 (control
group) had 100 cc. isotonic 0.9% as placebo, during the same time periods.
Results: In the postoperative period, the magnesium values were significantly higher in Group 1
than in Group 2 for all measurements. The use of amiodarone for total arrhythmia was significantly
more effective than prophylactic treatment with magnesium sulphate (p = 0.015). There was no
difference between the two drugs in preventing supraventricular arrhythmia, although amiodarone
significantly delayed the revealing time of atrial fibrillation (p = 0.026). Ventricular arrhythmia, in
the form of ventricular extra systole, was more common in the magnesium prophylaxis group. The
two groups showed no significant differences in other operative or postoperative measurements.
No side effects of the drugs were observed.
Conclusion:  Prophylactic use of magnesium sulphate and amiodarone are both effective at
preventing arrhythmia that may occur following coronary by-pass operations. Magnesium sulphate
should be used in prophylactic treatment since it may decrease arrhythmia at low doses. If
arrhythmia should occur despite this treatment, intervention with amiodarone may be preferable.
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Background
Postoperative rhythm disorders are a serious complica-
tion of open-heart surgery. The incidence of postoperative
supraventricular arrhythmias has been reported to be 11–
54%, and the incidence of ventricular arrhythmia to be
1.8–13%. [1]. Arrhythmias are frequently seen during the
first 48 hours following open-heart surgery, necessitating
effective postoperative monitoring. Knowledge of what
causes the development and progression of arrhythmia in
a postoperative patient may allow us to reduce the use of
pharmacological and electrical procedures aimed at
reducing the ventricular rate or ensuring normal sinus
rhythm.
The large majority of arrhythmia cases in coronary artery
bypass surgery (CABG), except insufficient revasculariza-
tion, can be controlled by electrical cardio versions. How-
ever, most medications currently used include beta-
blockers or negative inotropics and some of them increase
myocardial oxygen consumption as a side effect. The
decrease in the concentrations of ions such as potassium
and magnesium during the postoperative period is an
important factor in most of the cases of arrhythmia that
do not have organic causes (e.g. insufficient revasculariza-
tion and graft thrombosis). Identifying and detecting
these ionic imbalances may protect the heart from the side
effects of anti-arrhythmia treatments. Among the physio-
logical ions, magnesium plays an important role in pre-
serving cardiac rhythm by stabilizing membrane function
[1-3].
The aim of our study was to compare the effects of magne-
sium sulphate and amiodarone in the prevention and
treatment of ventricular and supraventricular arrhythmia
following CABG.
Methods
The study was performed on 192 patients who had under-
gone successful CABG. The local Ethics Committee
approved of the study, and personal informed consent
was taken.
Sixty-four patients were given 3 g of magnesium sulphate
(MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isot-
onic 0.9% solution intravenously for 2 hours at the fol-
lowing times: 12 hours prior to the operation,
immediately following the operation, and on postopera-
tive days 1, 2, and 3 (Group 1). The other group of 64
patients was given a preoperative amiodarone infusion of
1200 mg on the postoperative first day (Group 2). This
dose was followed by an oral dose of 600 mg/day. Sixty-
four patients in group 3 (control group) had 100 cc. isot-
onic 0.9% as placebo, during the same time periods.
During the same postoperative period, K+ replacements
[in the form of glucose-insulin-potassium (GIK) solution
(500 cc of 5% dextrose + 90 meq K+ + 12 U crystallized
insulin)] and Ca+2 replacements (1 g Ca-gluconate in 100
cc of isotonic 0.9% solution) were administered in order
to maintain a K+ concentration of at least 3.5–5.5 meq/L,
and a Ca+2 concentration of at least 8–9 meq/L. In order
to standardize the groups, patients were grouped based on
the following parameters: age, gender, use of calcium
channel blocker, use of beta-blocker, presence of diabetes,
presence of renal disorder, presence of chronic obstructive
pulmonary disease (COPD), history of non-cardiac oper-
ations, history of myocardial infarction (MI), classifica-
tion of New York Heart Association (NYHA), end diastolic
pressure (EDP), cross-clamp time, cardiopulmonary
bypass durations, and coronary bypass count (Table 1).
Anti-arrhythmia drugs used in the preoperative period
were halted 24 hours before the operation. Twelve deriva-
tion electrocardiographies of the patients were taken on
the morning of the operation day and patients showing
arrhythmia or ischemia were excluded from the study.
Operational procedure
Midazolam (0.03 mg/kg), hypnomidate (0.3 mg/kg),
phentanyl (5 μg/kg), and pancuronium bromide (0.1 mg/
kg) were used for anesthesia. When continuation was
needed, 5 μg/kg of phentanyl and 0.05 mg/kg of pancuro-
nium or vecuronium bromide were used.
All patients were subjected to standard median sternot-
omy. The left internal mammarian artery (LIMA) and
vena saphena magna from the lower extremity were dis-
sected and prepared. The arteria radialis was used for two
cases.
The LIMA graft was anastomosed to the left anterior
descending coronary artery (LAD) in all cases. With the
arterial cannulation from the aorta ascending and two-
stage venous cannulation from right atrial auricular, the
cardio-pulmonary bypass was introduced. A cardioplegia
cannula was placed in the aortic root and all the patients
were given cardioplegia by the anterograde way. A supply
of oxygenated blood was prepared throughout the opera-
tion, and the cardioplegic fluid prepared in this way was
administered using a "warm induction" procedure in
order to cause diastolic arrest. A total volume of 10 ml/kg
of cardioplegic fluid at a temperature of 37°C was intro-
duced into the heart through the aortic root. Cardioplegia
was periodically continued for periods of 15 minutes after
cooling. Warming was initiated as the LIMA-LAD anasto-
mosis was performed. Before the cross-clamp was
removed, a final dose of "hot shot" cardioplegic fluid (10
ml/kg, 37°C) was delivered in order to control reper-
fusion and prevent any reperfusion damage. ModerateJournal of Cardiothoracic Surgery 2009, 4:8 http://www.cardiothoracicsurgery.org/content/4/1/8
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hypothermia (28°C) was maintained throughout the
operation.
None of the patients in any group received any anti-
arrhythmia protocol other than those described.
Magnesium blood ion analysis: plasma Mg+2 levels were
determined by spectrophotometric analysis of venous
blood samples taken immediately after the operation and
on postoperative days 1, 2, and 3. Total Mg+2 levels were
recorded. At the same time, levels of Na+, K+, and Ca+2
were also determined, and their insufficiencies replaced in
the patients.
Liver function tests (SGOT, SGPT), urea and creatinine,
creatine kinase (CK), and creatine kinase MB (CK-MB)
were measured preoperatively, at preoperative time 0, and
postoperatively on days 1, 2, and 3. Cardiac troponin
(cTn-T) was measured preoperatively, and at 12 and 24
hours postoperatively in all cases.
Follow-up of cardiac rhythm and arrhythmia: Patients
were monitored during the preoperative period and for at
least 24 hours postoperatively. The rhythm follow-up of
cases was confirmed by ECG at 0, 6, and 12 hours postop-
eratively, as well as on postoperative days 1, 2, and 3.
Cases of ventricular tachycardia were medicated if they
caused multifocal or hypertensive at a frequency of more
than 10 per minute. Bigeminal and trigeminal rhythms
and ventricular early beats that persisted long less 30 sec-
onds and that did not include the properties mentioned
above were not medicated. In the case of supraventricular
arrhythmia, if the ion balance and K+ levels became nor-
mal but there was fast ventricular response AF, speed-lim-
iting anti-arrhythmic agents were used.
Exclusion criteria for this study were the following: Preop-
erative renal insufficiency, requirement of a second open-
heart operation, left ventricular aneurism, additional car-
diac pathology, and ischemia at the beginning of the oper-
ation (angina and ST alterations), off-pump CABS, and
single-vessel disorders.
Results and discussion
The groups were created based on several variables such
that they would not have significant differences in their
demographic or preoperative profiles. The groups did not
show a statistical difference in their mean left ventricle
ejection fraction (EF) (p > 0.05) (Table 1).
LIMA was used for LDA bypass in all patients. The radial
artery was used for two patients, while all other anastomo-
Table 1: Preoperative and demographic characteristics of the patients in the study sample.
Group 1 (Magnesium, n = 64) Group 2 (Amiodarone, n = 64) Group 3 (Control, n = 64) P value
Age (years) 58 ± 8 61 ± 6 57.6 ± 8.8 NS
Sex (M/F) 40/24 42/22 52/8 NS
History of MI 32 (50%) 30 (47%) 30 (47%) NS
Hypertension 23 (36%) 21 (33%) 23 (36%) NS
Smoking 23 (36%) 16 (25%) 23 (36%) NS
COPD 7 (11%) 8 (12. 5%) 8 (12. 5%) NS
PTCA-Stent 4 (6.2%) 6 (9.4%) 4 (6.2%) NS
Preoperative use of beta blocker 21 (33%) 23 (36%) 21 (33%) NS
BSA 1.79 ± 0.2 1.78 ± 0.3 1.78 ± 0.3 NS
LVEDP(mmHg) 13.6 ± 4.2 16.9 ± 6.5 14.6 ± 4.4 NS
Left ventricle EF (mean %) 45 ± 4 43 ± 3 44 ± 4 NS
Diabetes Mellitus 20 (31%) 18 (28%) 18 (28%) NS
MI, myocardial infarction; COPD, chronical obstructive pulmonary disease; NYHA, New York Heart Association; PTCA, percutan transluminal 
coronary angioplasty; BSA, body surface area; LVEDP, left ventricle end diastolic pressure; NS, not significant (p > 0.05).Journal of Cardiothoracic Surgery 2009, 4:8 http://www.cardiothoracicsurgery.org/content/4/1/8
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ses were performed using vena saphena grafts. The mean
number of grafts used was 3.1 ± 1.2 in Group 1, 3.2 ± 1.4
in Group 2 and 3.1 ± 1.4 in Group 3, and these means
were not significantly different. No significant difference
was observed between groups based on mean cross clamp
duration, perfusion duration, or use of inotropics. Simi-
larly, mean transfusion amount, duration of intubation,
duration of stay in the intensive care unit, and overall
length of hospital stay did not differ significantly between
the groups (Table 2).
Pre- and postoperative magnesium levels did not differ
between the three groups. In Group 1, all the measured
values showed a significant increase due to magnesium
sulphate prophylaxis treatment during the postoperative
period (day 0, p = 0.001; day 1, p = 0.02; day 2, p = 0.02;
day 3, p < 0.05 in other groups). However, a decrease was
observed in the level of magnesium following CABG dur-
ing the preoperative period. Potassium and calcium levels
were similar in both groups for in all measurements taken
to assess whether replacement therapy was needed (Table
3).
Values of CK-MB and cardiac troponin t (cTnT) did not
increase significantly for either group during the postop-
erative period (Table 4).
When postoperative arrhythmias were investigated, the
total arrhythmia count of all patients was 25 (19.5%). Of
these, 17 (13.35%) were supraventricular, and eight
(6.25%) were ventricular. All the cases of supraventricular
arrhythmia involved atrial fibrillation, and two patients in
the magnesium group showed pre-POAF atrial extrasysto-
les. No ventricular arrhythmia was detected in the amio-
darone group. Arrhythmias in the form of extrasystoles
were seen in eight patients of the magnesium group.
When the arrhythmias were more than 10 per minute,
lidocaine and metoprolol were administered. All eight
cases were detected at the end of the first dose of anti-
arrhythmic treatment. These cases were given additional
postoperative treatment of metoprolol (50 mg/day).
The AF that occurred postoperatively in the magnesium
group was treated with amiodarone infusion (900 mg/day
loading, 600 mg/day oral continuation), and all patients
recovered normal sinus rhythm. In the amiodarone
prophylaxis group, patients were given magnesium (3 g/
day), although two of seven patients (28.5%) recovered
normal sinus rhythm, while the other five (71.5%)
remained at AF. These latter patients continued to receive
amiodarone treatment, and no additional anti-arrhyth-
mic medication was given. On average, patients recovered
normal sinus rhythm by postoperative day 6 (Table 5).
Discussion
AF is an undesired but frequent complication of CABG
observed in 10–40% of cases. It prolongs a patient's stay
in the intensive care unit or hospital, and it disturbs a
Table 2: Preoperative and postoperative patient data.
Group 1 Group 2 Group 3 p
LIMA usage 64 (100%) 64 (100%) 64 (100%) NS
Saphenous graft usage 134 138 140 NS
Radial artery usage 1 (1.5%) 1 (1.5%) - NS
Mean number of grafts 3.1 ± 1.2 3.2 ± 1.4 3.1 ± 1.4 NS
Blood transfusion (units) 2 ± 1.5 2 ± 1.8 2 ± 1.8 NS
Duration of intubation (hours) 16.6 ± 3.3 15.2 ± 3.2 14.4 ± 3.5 NS
Duration of stay in intensive care unit 50.3 ± 5.3 49.2 ± 2.4 50 ± 5.5 NS
Discharge time (days) 7 ± 1 8 ± 2 7 ± 1 NS
Inotrope support 24 (37.5%) 20 (31.2%) 24 (37.5%) NS
Cross aortic clamp time (min) 82 ± 26 85 ± 22 80 ± 25 NS
Perfusion time (min) 104 ± 44 106 ± 30 100 ± 41 NS
NS, not significant (p > 0.05).Journal of Cardiothoracic Surgery 2009, 4:8 http://www.cardiothoracicsurgery.org/content/4/1/8
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patient's comfort. In addition, AF postpones full recovery
after CABG. Thus, many drugs have been used prophylac-
tically in order to prevent POAF: beta-blockers, calcium
channel blockers, magnesium sulphate, and amiadarone.
All of these drugs have different indications or counter
indications [2-4].
Reducing the frequency of arrhythmia of a patient after
CABG reduces both the duration of hospitalization and
medical costs. Studies have shown that 25–30% of the
patients had temporary supraventricular arrhythmia
attacks despite using β-blockers. As is widely known, β-
blockers are not indicated for those with poor ventricle
function who frequently demonstrate arrhythmia.
Instead, amiodarone is recommended for these patients
[4].
However, the sufficiency and reliability of amiodarone in
preventing arrhythmia is controversial. Oral amiodarone
is known to be insufficient for preventing postoperative
arrhythmia, but sometimes the preoperative loading dose
can prove sufficient. Amiodarone given during the preop-
erative period has been reported to react with anesthetic
agents and cause pulmonary dysfunction, hypotension,
hepatic dysfunction, and low heart flow. However, Daoud
et al. have reported that preoperative amiodarone use
does not increase the risk of postoperative mortality and
morbidity [4,5]. Similarly, we did not observe any side
effects in the amiodarone group in the present study.
According to our observations, both drugs are safe.
Our results indicate that amiodarone is significantly more
effective than magnesium sulphate in treating total
arrhythmia. However, this may be because the ventricular
extrasystoles frequently disappear in the absence of any
medication. The two groups showed no differences in the
rate of recovery from supraventricular arrhythmia.
Table 3: Magnesium values of patients
Group 1 Group 2 Group 3 P value
Magnesium (mg/dL) Preoperative 1.9 ± 0.3 1.9 ± 0.2 2.1 ± 0.3 NS
Perioperative 1.7 ± 0.2 1.7 ± 0.3 1.8 ± 0.3 NS
0* 3.6 ± 0.4 1.5 ± 0.2 1.8 ± 0.3 0.001**
1* 3.1 ± 0.7 1.6 ± 0.2 1.7 ± 0.3 0.02**
2* 3.0 ± 0.6 1.6 ± 0.3 1.7 ± 0.3 0.02**
3* 2.9 ± 0.6 1.7 ± 0.2 1.8 ± 0.3 0.04**
*Postoperative days; ** Significant (Difference between Group 1 and other groups). NS, not significant (p > 0.05).
Table 4: Enzyme values of patients.
Group 1 Group 2 Group 3 P value
CK-MB (U/L) Preoperative 29 ± 2.5 17 ± 2.1 17 ± 2.5 NS
12 hr 53 ± 4.1 108 ± 5.5 83 ± 3.7 NS
24 hr 74 ± 3.6 77 ± 3.7 63 ± 4.1 NS
3 day 42 ± 2.3 47 ± 3.2 44 ± 2.3 NS
cTn-T (ng/mL) Preoperative 1.23 ± 0.2 1.91 ± 0.3 1,61 ± 0.4 NS
12 hr 2.11 ± 0.3 2.45 ± 0.4 2,53 ± 0.3 NS
24 hr 1.31 ± 0.4 1.54 ± 0.2 1,27 ± 0.4 NS
3 day 0.9 ± 0.2 0.7 ± 0.1 0.8 ± 0.2 NS
CK-MB, creatine kinase-MB; cTn-T, cardiac troponin-T; NS, Not Significant (p > 0.05).Journal of Cardiothoracic Surgery 2009, 4:8 http://www.cardiothoracicsurgery.org/content/4/1/8
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Magnesium is a cation that functions by lengthening the
refractory period at the atrioventricular node. Thus, mag-
nesium likely has an important role in preventing and
treating atrial fibrillation, especially considering that
serum magnesium levels below 0.8 mmol/L trigger atrial
fibrillation. Thus, dose loading with magnesium can pre-
vent the arrhythmia caused by the postoperative decrease
in this caution.
In our study we observed that the serum magnesium lev-
els were low in the postoperative period, although never
below 0.8 mmol/L [2].
Many comparative studies and meta-analyses have been
published on this issue. In a meta-analysis evaluating
atrial fibrillation after CABG, the frequency of POAF was
determined to be 32.3%. POAF is frequently concomitant
with renal insufficiency and infection. In this meta-analy-
sis, preoperative COPD and older age were determined to
be risk factors for POAF. The investigators concluded that
atrial fibrillation is an important complication of CABG,
and they suggested preventing it by administering β-
blockers and ACE inhibitors [6].
Çağlı et al. performed a study that combined amiodarone
and MgSO4, and they concluded that together these agents
are tolerable and work more effectively in high-risk
patients than they do on their own [7]. A different study
showed that older age and lower magnesium plasma lev-
els are the most important risk factors of POAF. This same
study reported that amiodarone was effective for POAF,
whereas magnesium prophylaxis had no effect [5-8]. In
our study, we administered amiodarone to patients with
AF despite magnesium prophylaxis; we administered ami-
odarone orally, following an initial loading dose.
Studies have examined the effects of medications other
than prophylaxis following AF. Parenteral magnesium
was reported to be superior to amiodarone in studies of
acute atrial tachyarrhythmia [9]. Davey et al. have shown
that magnesium sulphate slows the heart rate and pre-
vents supraventricular arrhythmia. They also found that
AF frequently returns to normal sinus rhythm in patients
treated with magnesium sulphate. Lastly, they reported
that magnesium-related hypotension and bradycardia are
potential risk factors for AF [10].
In a meta-analysis evaluating eight different clinical stud-
ies, the use of different doses of magnesium sulphate, pla-
cebo, amiodarone, and diltiazem following atrial
fibrillation was examined. During the first hour following
its application, magnesium was found to be superior to
other anti-arrhythmics for controlling ventricular speed
(patients with a heartbeat of less than 100/min). Magne-
sium was also significantly more effective than placebo or
diltiazem for restoring normal sinus rhythm within the
first 15 hours. As a result, magnesium sulphate effectively
controls heart rhythm following AF [11]. In another
study, magnesium was found to be effective at preventing
postoperative ventricular arrhythmia in a dose-dependent
manner [12].
Conclusion
The types of patients examined in this study require treat-
ment for their atrial fibrillation. Our study shows that
both amiodarone and magnesium sulphate work safely
and sufficiently rapidly for this purpose. Our clinic
already uses amiodarone frequently, and this study shows
that magnesium is also effective at treating postoperative
arrhythmia. In fact, using magnesium may avoid low
postoperative levels of magnesium and its concomitant
Table 5: Postoperative arrhythmia observed in the patient sample.
Group 1 (n = 64) Group 2 (n = 64) Group 3 (n = 64) P value
Postoperative arrhythmia 18 (28.1%) 7 (10.9%) 30 (46%) 0.015*
Supraventricular arrhythmia 10 (16.7%) 7 (10.9%) 20 (31%) NS
Atrial extrasystole 2 (3.3%) 0 0 NS
Atrial fibrillation 10 (16.7%) 7 (10.9%) 20 (37.3%) NS
AF exit time (hours) 49 ± 15 123 ± 27 48 ± 17 0.026*
Ventricular arrhythmia 8 (12.5%) 0 10 (%15) 0.001*
Ventricular extrasystole 8 (12.5%) 0 10 (%15) 0.001*
* Significant (Difference between Group 1 and Group 2).Publish with BioMed Central    and   every 
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side effects, as well as postoperative atrial fibrillation.
Thus, we suggest routine magnesium sulphate administra-
tion in patients undergoing open-heart surgery.
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